Which finding best distinguishes RAS mutations from MYC translocations as mechanisms of oncogenic transformation?

Question

Accepted Answer

D. RAS mutations cause sustained proliferative signaling through constitutive activation of growth pathways, whereas MYC translocations result in overexpression of a transcription factor driving uncontrolled cell cycle progression. ## RAS Mutations vs. MYC Translocations: Mechanistic Distinction

### Molecular Mechanism Comparison

| Feature | RAS Mutations | MYC Translocations |
|---------|---------------|-------------------|
| **Type of alteration** | Point mutation (gain-of-function) | Chromosomal translocation |
| **Protein affected** | RAS (small GTPase signaling protein) | MYC (transcription factor) |
| **Mechanism of action** | Constitutive activation of MAPK/ERK and PI3K/AKT pathways | Juxtaposition to immunoglobulin or TCR promoter → overexpression |
| **Cellular effect** | Sustained proliferative signaling | Uncontrolled cell cycle progression & apoptosis resistance |
| **Tumor types** | Pancreatic (90%), colorectal (50%), lung, melanoma | Burkitt lymphoma (80%), diffuse large B-cell lymphoma |
| **Frequency in solid tumors** | Very common | Rare in solid tumors |

### Key Point

**High-Yield:** RAS acts as a **molecular switch** in cytoplasmic signaling cascades, while MYC acts as a **transcriptional driver** in the nucleus. RAS mutations lock the switch in the "ON" position; MYC translocations place the gene under the control of constitutively active promoters.

### Clinical Pearl

**Key Point:** MYC translocations are pathognomonic for Burkitt lymphoma (t(8;14) in 80% of cases). RAS mutations are ubiquitous in solid tumors but rare in lymphomas.

### Mnemonic

**RAS = Relay (signal relay in cytoplasm); MYC = Master transcription factor (nucleus)**

Answer

A. RAS mutations are found exclusively in adenocarcinomas, while MYC translocations occur only in hematologic malignancies

Answer

B. RAS mutations are loss-of-function events, whereas MYC translocations are gain-of-function events

Answer

C. RAS mutations activate apoptosis, whereas MYC translocations inhibit apoptosis

Which finding best distinguishes RAS mutations from MYC translocations as mechanisms of oncogenic transformation?

Explanation

RAS Mutations vs. MYC Translocations: Mechanistic Distinction

Molecular Mechanism Comparison

Key Point

Clinical Pearl

Mnemonic

Practice similar questions

Join our NEET PG community

Feature	RAS Mutations	MYC Translocations
Type of alteration	Point mutation (gain-of-function)	Chromosomal translocation
Protein affected	RAS (small GTPase signaling protein)	MYC (transcription factor)
Mechanism of action	Constitutive activation of MAPK/ERK and PI3K/AKT pathways	Juxtaposition to immunoglobulin or TCR promoter → overexpression
Cellular effect	Sustained proliferative signaling	Uncontrolled cell cycle progression & apoptosis resistance
Tumor types	Pancreatic (90%), colorectal (50%), lung, melanoma	Burkitt lymphoma (80%), diffuse large B-cell lymphoma
Frequency in solid tumors	Very common	Rare in solid tumors